With an Area Under The Curve (AUC) of 0.87, the Cardio Explorer has an accuracy comparable to the best imaging techniques.
Cardio Explorer calculates the pre-test probability required by medical guidelines (ESC 2019) with higher precision than existing methods.
Cardio Explorer enables precise risk stratification of patients with suspected CHD. This conserves scarce specialist resources and treats patients efficiently.
The Cardio Explorer is approved in Switzerland and all EU countries.
Cardio Explorer has been validated in three clinical trials with over 2,000 patients, in high and low prevalence populations, and showed tremendously high accuracy in all studies (AUC of 0.87). The broad validation is a prerequisite for use in primary diagnostics and prevention.
CHD reflects a system-wide and highly complex pathophysiology that requires a comprehensive combinatorial assessment of all risk factors. Artificial intelligence (AI) allows efficient and personalized assessment.
From more than 100 factors, the 32 relevant factors were identified via an evolutionary learning process: